TY  - JOUR
AU  - Szabó-Taylor, Katalin
AU  - Molnár, Mária Judit
TI  - A spinalis izomatrophia személyre szabott terápiás lehetőségei
JF  - IDEGGYOGYASZATI SZEMLE / CLINICAL NEUROSCIENCE
J2  - IDEGGYOGY SZEMLE
VL  - 76
PY  - 2023
IS  - 3-4
SP  - 77
EP  - 94
PG  - 18
SN  - 0019-1442
DO  - 10.18071/isz.76.0077
UR  - https://m2.mtmt.hu/api/publication/33721840
ID  - 33721840
N1  - Export Date: 26 July 2023            
            CODEN: IDSZA            
            Correspondence Address: Szabó-Taylor, K.; Semmelweis Egyetem, Nagyvárad tér 4., Hungary; email: szabo-taylor.katalin@med.semmelweis-univ.hu
AB  - Spinal muscular atrophy (SMA) is an autosomal recessive disease leading to progressive muscle weakness and atrophy, in severe cases also affecting the bulbar and respiratory muscles.The clinical spectrum of the disease is extremely variable, in the most severe cases resulting in perinatal death, while at the least severe end of the spectrum causing some motor deficits in old age without the loss of ambulation. Spinal muscular atrophy care has changed dramatically in recent years due to the availability of new therapeutic options. The FDA approved nusinersen in 2016, this was followed by the approval of onasemnogene abeparvovec in 2019 and risdiplam in 2020. The EMA approved all three therapies a year later. Two of the threapies work at the pre-mRNA level, one at the DNA level. The clinical studies leading to the approval of the three drugs included patients of different ages and clinical conditions, and utilised partly different motor and functional scales. Therefore, direct comparison of these clinical studies is not possible. However, an increasing amount of real-world data contribute to the better understanding of the efficacy of the different therapies for patients of different ages and clinical conditions, in a real-world setting. Thus, the question may arise “Which is the best SMA therapy?”. This is an impossible question to answer. Indeed the question “Which therapy is the most suitable for a certain patient at a certain time?” is much more realistic. Here, we provide a brief overview of the objectively measurable results of the three therapies to date and an outlook into future therapeutic avenues.
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Alasztics, Bálint
AU  - Kovács, Árpád Ferenc
AU  - Pállinger, Éva
AU  - Szabó-Taylor, Katalin
AU  - Szabó, Gábor
AU  - Molvarec, Attila
AU  - Koller, Ákos
AU  - Rigó, János
TI  - Upregulation of exofacial peroxiredoxin-thioredoxin system of lymphocytes and monocytes in preeclampsia
JF  - PREGNANCY HYPERTENSION
J2  - PREGNANCY HYPERTENS
VL  - 31
PY  - 2023
SP  - 54
EP  - 59
PG  - 6
SN  - 2210-7789
DO  - 10.1016/j.preghy.2022.12.002
UR  - https://m2.mtmt.hu/api/publication/33334444
ID  - 33334444
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Tóth, Eszter Ágnes
AU  - Turiák, Lilla
AU  - Visnovitz, Tamás
AU  - Cserép, Csaba
AU  - Türk-Mázló, Anett
AU  - Sódar, Barbara
AU  - Försönits, András
AU  - Petővári, Gábor
AU  - Sebestyén, Anna
AU  - Komlósi, Zsolt
AU  - Drahos, László
AU  - Kittel, Ágnes
AU  - Nagy, György
AU  - Bácsi, Attila
AU  - Dénes, Ádám
AU  - Song Gho, Yong
AU  - Szabó-Taylor, Katalin
AU  - Buzás, Edit Irén
TI  - Formation of a protein corona on the surface of extracellular vesicles in blood plasma
JF  - JOURNAL OF EXTRACELLULAR VESICLES
J2  - J EXTRACELLULAR VESICL
VL  - 10
PY  - 2021
IS  - 11
PG  - 26
SN  - 2001-3078
DO  - 10.1002/jev2.12140
UR  - https://m2.mtmt.hu/api/publication/32189675
ID  - 32189675
N1  - Katalin É Szabó-Taylor and Edit I Buzás contributed equally.

Funding information
National Research, Development and Innovation Office NKFIH, Hungary, Grant/Award Numbers:
OTKA11958, OTKA120237, OTKA125337, OTKA K131479, OTKA PD 121187, OTKA FK 131603,
OTKA 131762, NVKP_16-1-2016-0017; Higher Education Institutional Excellence Program –
Therapeutic development, Grant/Award Numbers:ÚNKP-19-3-I-SE-45, ÚNKP-20-5; New National
Excellence Program of the Ministry for Innovation and Technology; Ministry for National Economy
of Hungary, Grant/Award Numbers: VEKOP-2.3.2-16-2016-00002, VEKOP-2.3.3-15-2016-00016,

EFOP-3.6.3-VEKOP-16-2017-00009; Az orvos-,egészségtudományi- és gyógyszerészképzés
tudományos muhelyeinek fejlesztése; European  ̋Commission, Grant/Award Number: H2020-MSCA-ITN-2017-722148 TRAIN EV; Hungarian Academy of Sciences: János Bolyai Research Schol-
arship and “Momentum”, Grant/Award Number: LP2016-4/2016; European Research Council,
Grant/Award Numbers: ERC-CoG 724994, H2020-ITN-2018-813294-ENTRAIN; EU’s Horizon 2020
research and innovation program, Grant/Award Number: 739593
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Tóth, Eszter Ágnes
AU  - Szabó-Taylor, Katalin
AU  - Visnovitz, Tamás
AU  - Nagy, György
AU  - Buzás, Edit Irén
TI  - Surface protein cargo of extracellular vesicles in blood plasma; the effect of an inflammatory disease on the vesicle surface protein interactome
JF  - JOURNAL OF EXTRACELLULAR VESICLES
J2  - J EXTRACELLULAR VESICL
VL  - 8
PY  - 2019
IS  - Suppl. 1
SP  - 140
EP  - 140
PG  - 1
SN  - 2001-3078
UR  - https://m2.mtmt.hu/api/publication/30604411
ID  - 30604411
LA  - English
DB  - MTMT
ER  - 

TY  - CHAP
AU  - Jaeger, M.
AU  - Kirleis, W.
AU  - Kiss, Viktória
AU  - Kulcsár, Gabriella
AU  - Müller, J.
AU  - Staniuk, R.
AU  - Szabó-Taylor, Katalin
ED  - Mateusz, Jaeger
ED  - Kulcsár, Gabriella
ED  - Nicole, Taylor
ED  - Robert, Staniuk
TI  - Kakucs Archaeological Expedition
T2  - Kakucs-Turján a Middle Bronze Age multi-layered fortified settlement in Central Hungary
PB  - Dr. Rudolf Habelt GmbH
CY  - Bonn
SN  - 9783774941496
T3  - Studien zur Archäologie in Ostmitteleuropa = Studia nad pradziejami Europy Środkowej ; 18.
PY  - 2018
SP  - 13
EP  - 21
PG  - 9
UR  - https://m2.mtmt.hu/api/publication/30391582
ID  - 30391582
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Buzás, Edit Irén
AU  - Tóth, Eszter Ágnes
AU  - Sódar, Barbara
AU  - Szabó-Taylor, Katalin
TI  - Molecular interactions at the surface of extracellular vesicles
JF  - SEMINARS IN IMMUNOPATHOLOGY
J2  - SEMIN IMMUNOPATHOL
VL  - 40
PY  - 2018
IS  - 5
SP  - 453
EP  - 464
PG  - 12
SN  - 1863-2297
DO  - 10.1007/s00281-018-0682-0
UR  - https://m2.mtmt.hu/api/publication/3403202
ID  - 3403202
N1  - Buzás E.I. and Tóth E.Á. contributed equally to this work.
AB  - Extracellular vesicles such as exosomes, microvesicles, apoptotic bodies, and large oncosomes have been shown to participate in a wide variety of biological processes and are currently under intense investigation in many different fields of biomedicine. One of the key features of extracellular vesicles is that they have relatively large surface compared to their volume. Some extracellular vesicle surface molecules are shared with those of the plasma membrane of the releasing cell, while other molecules are characteristic for extracellular vesicular surfaces. Besides proteins, lipids, glycans, and nucleic acids are also players of extracellular vesicle surface interactions. Being secreted and present in high number in biological samples, collectively extracellular vesicles represent a uniquely large interactive surface area which can establish contacts both with cells and with molecules in the extracellular microenvironment. Here, we provide a brief overview of known components of the extracellular vesicle surface interactome and highlight some already established roles of the extracellular vesicle surface interactions in different biological processes in health and disease.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Osteikoetxea, Xabier
AU  - Benke, Márton
AU  - Rodriguez, M
AU  - Pálóczi, Krisztina
AU  - Sódar, Barbara
AU  - Szvicsek, Zsuzsanna
AU  - Szabó-Taylor, Katalin
AU  - Visnovitzné Dr Vukman, Krisztina
AU  - Kittel, Ágnes
AU  - Wiener, Zoltán
AU  - Vékey, Károly
AU  - Harsányi, László
AU  - Szűcs, Ákos
AU  - Turiák, Lilla
AU  - Buzás, Edit Irén
TI  - Detection and proteomic characterization of extracellular vesicles in human pancreatic juice
JF  - BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
J2  - BIOCHEM BIOPH RES CO
VL  - 499
PY  - 2018
IS  - 1
SP  - 37
EP  - 43
PG  - 7
SN  - 0006-291X
DO  - 10.1016/j.bbrc.2018.03.107
UR  - https://m2.mtmt.hu/api/publication/3353499
ID  - 3353499
N1  - Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary            
            1st Department of Surgery, Semmelweis University, Budapest, Hungary            
            Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway            
            Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary            
            Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary            
            MTA-SE Immune-Proteogenomics Extracellular Vesicles Research Group, Budapest, Hungary            
            Cited By :34            
            Export Date: 22 February 2024            
            CODEN: BBRCA            
            Correspondence Address: Buzás, E.I.Nagyvárad tér 4, Hungary; email: buzas.edit@med.semmelweis-univ.hu            
            Chemicals/CAS: cystic fibrosis transmembrane conductance regulator, 126880-72-6; mucin 1, 212255-06-6; ABC transporter subfamily B, 149200-37-3, 208997-77-7; ABCB1 protein, human; ATP Binding Cassette Transporter, Sub-Family B; Biomarkers, Tumor; CFTR protein, human; Cystic Fibrosis Transmembrane Conductance Regulator; Mucins; Proteome            
            Funding details: BM1202 ME HAD, PITN-GA-2011-289033            
            Funding details: Hungarian Scientific Research Fund, OTKA, 118018, 11958, 120237, NVKP_16-1-2016-0007 41204, NVKP_16-1-2016-0017, PD104369, PD112085, VEKOP-2.3.2-16-2016-00002, VEKOP-2.3.3-15-2016-00016            
            Funding details: MedInProt Protein Science Research Synergy Program            
            Funding text 1: This work was supported by FP7-PEOPLE-2011-ITN–PITN-GA-2011-289033 , BM1202 ME HAD , National Scientific Research Program of Hungary (OTKA) 118018 , 11958 , 120237 , PD104369 , PD112085 , NVKP_16-1-2016-0007 41204 , NVKP_16-1-2016-0017 , Ministry for National Economy of Hungary VEKOP-2.3.2-16-2016-00002 and VEKOP-2.3.3-15-2016-00016 and Protein Science Research Synergy Program (MedInProt) Grant III .
AB  - AIMS: The prognosis of patients with pancreatic cancer has remained virtually unchanged with a high mortality rate compared to other types of cancers. An earlier detection would provide a time window of opportunity for treatment and prevention of deaths. In the present study we investigated extracellular vesicle (EV)-associated potential biomarkers for pancreatic cancer by directly assessing EV size-based subpopulations in pancreatic juice samples of patients with chronic pancreatitis or pancreatic cancer. In addition, we also studied blood plasma and pancreatic cancer cell line-derived EVs. METHODS: Comparative proteomic analysis was performed of 102EV preparations from human pancreatic juices, blood, and pancreatic cancer cell lines Capan-1 and MIA PaCa-2. EV preparations were also characterized by electron microscopy, tunable resistive pulse sensing, and flow cytometry. RESULTS: Here we describe the presence of EVs in human pancreatic juice samples. Pancreatic juice EV-associated proteins that we identified as possible candidate markers for pancreatic cancer included mucins, such as MUC1, MUC4, MUC5AC, MUC6 and MUC16, CFTR, and MDR1 proteins. These candidate biomarkers could also be detected by flow cytometry in EVs found in pancreatic juice and those secreted by pancreatic cancer cell lines. CONCLUSIONS: Together our data show that detection and characterization of EVs directly in pancreatic juice is feasible and may prove to be a valuable source of potential biomarkers of pancreatic cancer.
LA  - English
DB  - MTMT
ER  - 

TY  - CONF
AU  - Kulcsár, Gabriella
AU  - Gál, Erika
AU  - Szabó-Taylor, Katalin
AU  - Jaeger, M
ED  - Vicze, Magdolna
ED  - Kovács, Gabriella
TI  - Technológiák Kakucson – csonteszközök használata egy középső bronzkori településen (KEX BONE)
T2  - Momos X. Őskori technikák, őskori technológiák
PB  - Matrica Múzeum
C1  - Százhalombatta
PY  - 2017
SP  - 28
UR  - https://m2.mtmt.hu/api/publication/30391726
ID  - 30391726
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Németh, Andrea
AU  - Orgován, Norbert
AU  - Sódar, Barbara
AU  - Osteikoetxea, Xabier
AU  - Pálóczi, Krisztina
AU  - Szabó-Taylor, Katalin
AU  - Visnovitzné Dr Vukman, Krisztina
AU  - Kittel, Ágnes
AU  - Turiák, Lilla
AU  - Wiener, Zoltán
AU  - Tóth, Sára
AU  - Drahos, László
AU  - Vékey, Károly
AU  - Horváth, Róbert
AU  - Buzás, Edit Irén
TI  - Antibiotic-induced release of small extracellular vesicles (exosomes) with surface-associated DNA
JF  - SCIENTIFIC REPORTS
J2  - SCI REP
VL  - 7
PY  - 2017
PG  - 16
SN  - 2045-2322
DO  - 10.1038/s41598-017-08392-1
UR  - https://m2.mtmt.hu/api/publication/3254659
ID  - 3254659
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Szabó-Taylor, Katalin
AU  - Tóth, Eszter Ágnes
AU  - Balogh, AM
AU  - Sódar, Barbara
AU  - Kadar, L
AU  - Pálóczi, Krisztina
AU  - Fekete, Nóra
AU  - Németh, Andrea
AU  - Osteikoetxea, Xabier
AU  - Visnovitzné Dr Vukman, Krisztina
AU  - Holub Marianna, Csilla
AU  - Pállinger, Éva
AU  - Nagy, György
AU  - Winyard, PG
AU  - Buzás, Edit Irén
TI  - Monocyte activation drives preservation of membrane thiols by promoting release of oxidised membrane moieties via extracellular vesicles
JF  - FREE RADICAL BIOLOGY AND MEDICINE
J2  - FREE RADICAL BIO MED
VL  - 108
PY  - 2017
SP  - 56
EP  - 65
PG  - 10
SN  - 0891-5849
DO  - 10.1016/j.freeradbiomed.2017.03.016
UR  - https://m2.mtmt.hu/api/publication/3214054
ID  - 3214054
N1  - Funding Agency and Grant Number: National Scientific Research Program of Hungary (OTKA) [PD 104369, PD 112085, 111958, 120237]; BMBS COST ActionEuropean Cooperation in Science and Technology (COST) [BM1202]; Janos Bolyai Research Fellowship of the Hungarian Academy of SciencesHungarian Academy of Sciences
            Funding text: This work was supported by the National Scientific Research Program of Hungary (OTKA) grant no. PD 104369 to KSZT, grant no. PD 112085 to VVK and grant no. 111958 and 120237 to EIB, the MEDINPROT Program (Synergy programs I, III and IV), BMBS COST Action (BM1202), the Janos Bolyai Research Fellowship of the Hungarian Academy of Sciences (to KVV) and the Kerpel Fronius Program of the Semmelweis University (Astellas Pharma Grant to BSW). We are grateful to Prof DA Lawrence (Wadsworth Center, New York State Department of Health, Empire State Plaza, Albany, NY, USA) for helpful communications regarding fluorescent maleimide labelling of leukocytes. Many thanks to Ms Andrea Orban for skillful assistance in the tissue culture laboratory. We are greatly indebted to all blood donors without whom this study would not have been possible.
AB  - The redox state of cellular exofacial molecules is reflected by the amount of available thiols. Furthermore, surface thiols can be considered as indicators of immune cell activation. One group of thiol containing proteins, peroxiredoxins, in particular, have been associated with inflammation. In this study, we assessed surface thiols of the U937 and Thp1 monocyte cell lines and primary monocytes in vitro upon inflammatory stimulation by irreversibly labelling the cells with a fluorescent derivative of maleimide. We also investigated exofacial thiols on circulating blood mononuclear cells in patients with rheumatoid arthritis and healthy controls. When analysing extracellular vesicles, we combined thiol labelling with the use of antibodies to specific CD markers to exclude extracellular vesicle mimicking signals from thiol containing protein aggregates. Furthermore, differential detergent lysis was applied to confirm the vesicular nature of the detected extracellular events in blood plasma. We found an increase in exofacial thiols on monocytes upon in vitro stimulation by LPS or TNF, both in primary monocytes and monocytic cell lines (p<0.0005). At the same time, newly released extracellular vesicles showed a decrease in their exofacial thiols compared with those from unstimulated cells (p<0.05). We also found a significant elevation of surface thiols on circulating monocytes in rheumatoid arthritis patients (p<0.05) and newly released extracellular vesicles of isolated CD14+ cells from rheumatoid arthritis patients had decreased thiol levels compared with healthy subjects (p<0.01). Exofacial peroxiredoxin 1 was demonstrated on the surface of primary and cultured monocytes, and the number of peroxiredoxin 1 positive extracellular vesicles was increased in rheumatoid arthritis blood plasma (p<0.05). Furthermore, an overoxidised form of peroxiredoxin was detected in extracellular vesicle-enriched preparations from blood plasma. Our data show that cell surface thiols play a protective role and reflect oxidative stress resistance state in activated immune cells. Furthermore, they support a role of extracellular vesicles in the redox regulation of human monocytes, possibly representing an antioxidant mechanism.
LA  - English
DB  - MTMT
ER  -